Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - le myélome multiple - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. en association avec le bortézomib, la thalidomide et la dexaméthasone pour le traitement de patients adultes atteints de myélome multiple nouvellement diagnostiqué, qui sont admissibles à une greffe de cellules souches autologues. en combinaison avec le lénalidomide et de la dexaméthasone, ou le bortézomib et la dexaméthasone, pour le traitement de patients adultes atteints de myélome multiple qui ont reçu au moins un traitement antérieur. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. en tant que monothérapie pour le traitement des patients adultes en rechute et réfractaire myélome multiple, dont le traitement antérieur inclus un inhibiteur du protéasome et un agent immunomodulateur et qui ont démontré la progression de la maladie sur la dernière thérapie. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Canada - français - Health Canada

janssen inc - daratumumab - solution - 1800mg - daratumumab 1800mg - antineoplastic agents

Canada - français - Health Canada

janssen inc - daratumumab - solution - 100mg - daratumumab 100mg - antineoplastic agents

Canada - français - Health Canada

janssen inc - daratumumab - solution - 400mg - daratumumab 400mg - antineoplastic agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - solution injectable - daratumumabum 1800 mg, hyaluronidasum humanum adnr, histidinum, histidini hydrochloridum monohydricum, sorbitolum 735.1 mg, methioninum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 15 ml. - multiples myelom, leichtketten-amyloidose - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - solution à diluer pour perfusion - daratumumabum 100 mg, acidum aceticum glaciale, natrii acetas trihydricus, natrii chloridum, mannitolum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml corresp. natrium 9.4 mg. - multiples myelom - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - solution à diluer pour perfusion - daratumumabum 400 mg, acidum aceticum glaciale, natrii acetas trihydricus, natrii chloridum, mannitolum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 20 ml corresp. natrium 37.7 mg. - multiples myelom - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - solution à diluer pour perfusion - daratumumabum 100 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 273.3 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - multiples myelom - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - solution à diluer pour perfusion - daratumumabum 400 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 1093.0 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - multiples myelom - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - le myélome multiple - agents antinéoplasiques - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.